Inhibiting DDR components, like PARP, ATR, WEE1, CHK1/2, ATM, and DNA-PKs, is under evaluation in early-phase studies for multiple myeloma and other hematological malignancies showing promising preliminary signals of activity [65,66,67]. This evidence concerns the gene CHEK1 and plasma cell myeloma.